SillaJen Competitors and Similar CompaniesClear all
SillaJen's competitors and similar companies include Epizyme, Achilles Therapeutics, Symphogen and G1 Therapeutics.
 SillaJen SillaJen is a biotechnology company focused on engineering and developing oncolytic virus immunotherapeutics. |  Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. | ||
Founding Date | Founding Date 2003 | Founding Date 2007 | Founding Date 2016 | Founding Date 2000 | Founding Date 2008 |
Type | Type Public | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations KR HQ San Francisco, US | Locations Cambridge, US HQ | Locations London, GB HQ Stevenage, GB | Locations Ballerup, DK HQ Somerville, US | Locations Durham, US HQ |
Employees | Employees 4316% increase | Employees 20364% increase | Employees 695% decrease | Employees 196 | Employees 17015% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 250.8 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 377.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) ₩9.2b (FY, 2025) | Revenue (est.) $37.4m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $82.5m (FY, 2023) |
Cost of goods | Cost of goods (₩1k) (FY, 2025) | Cost of goods $10.5m (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) |
Gross profit | Gross profit ₩9.9b (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $75.3m (FY, 2023) |
Net income | Net income (₩24.2b) (FY, 2025) | Net income ($251.1m) (FY, 2021) | Net income ($69.7m) (FY, 2023) | Net income N/A | Net income ($48m) (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised $ 12m | Total funding raised $ 51.5m | Total funding raised $ 138.1m | Total funding raised $ 387.2m | Total funding raised $ 289.6m |
For sources of this data, please see the company profile
View Company Profiles
Epizyme
HQ
Cambridge, US
Employees
203
Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
View companyAchilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View company
Symphogen
HQ
Ballerup, DK
Employees
196
Symphogen is a biotech company focused on oncology and immuno-oncology.
View companyG1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View company